Serotonin Release -- The Primary Engine
Fenfluramine's defining mechanism is substrate-type serotonin release. Like MDMA and other serotonin releasing agents, fenfluramine enters presynaptic serotonergic terminals through the serotonin transporter (SERT) -- it is a substrate for the transporter, not a blocker. Once inside the terminal, it does two things simultaneously:
Reverses SERT function. The transporter normally pumps serotonin into the cell from the synapse. Fenfluramine forces it to work in reverse, causing carrier-mediated efflux of serotonin into the synaptic cleft. This is non-exocytotic release -- it bypasses the normal vesicle-fusion machinery entirely.
Disrupts vesicular storage. Fenfluramine is also a substrate for the vesicular monoamine transporter (VMAT), which normally packages serotonin into synaptic vesicles for regulated release. By interfering with VMAT, fenfluramine dumps cytoplasmic serotonin out of its vesicular compartments, increasing the pool of free serotonin available for reverse transport through SERT.
The result is a massive, sustained increase in extracellular serotonin concentrations -- conceptually similar to MDMA, but with a critical difference in selectivity. Fenfluramine releases serotonin with far greater potency than it releases dopamine or norepinephrine. This serotonergic selectivity explains why fenfluramine feels nothing like classical amphetamine: it produces sedation, appetite suppression, and anxiolysis rather than the euphoric drive and focus associated with dopaminergic stimulation.
Norfenfluramine -- The Metabolite That Changed Everything
Fenfluramine undergoes extensive hepatic N-deethylation (primarily via CYP1A2, CYP2B6, and CYP2D6) to form norfenfluramine, which is pharmacologically active and reaches approximately half the plasma concentration of the parent compound at steady state. Norfenfluramine has its own receptor profile that differs markedly from fenfluramine itself:
5-HT2B receptor: High-affinity full agonist (Ki = 27 nM for d-norfenfluramine, 65 nM for l-norfenfluramine). This is the receptor responsible for cardiac valvulopathy -- 5-HT2B activation on valvular interstitial cells drives pathological cell proliferation and fibrotic tissue deposition. The potency at this receptor is striking: norfenfluramine is among the most potent known 5-HT2B agonists, comparable to ergot alkaloids associated with the same valvular pathology.
5-HT2C receptor: High-affinity agonist (Ki = 56 nM for d-norfenfluramine, 99 nM for l-norfenfluramine). This is the receptor responsible for appetite suppression -- 5-HT2C agonism in the hypothalamus reduces food intake through activation of POMC (pro-opiomelanocortin) neurons in the arcuate nucleus.
5-HT2A receptor: Moderate-affinity agonist. This is the receptor responsible for the hallucinogenic effects observed at high doses -- the same receptor through which LSD, psilocybin, and other classical psychedelics produce their characteristic perceptual distortions.
Additional Mechanisms
Fenfluramine has several secondary pharmacological actions that contribute to its complex profile:
Sigma-1 receptor positive modulation: Sub-micromolar affinity. The sigma-1 receptor is increasingly recognized as important in seizure control, which may contribute to fenfluramine's anticonvulsant efficacy beyond its serotonergic actions.
GABAergic enhancement: Fenfluramine enhances GABAergic neurotransmission and has been shown to restore dendritic arborization of GABAergic neurons in animal models of Dravet syndrome. This mechanism is particularly relevant to its use in epilepsy.
Norepinephrine release: Fenfluramine is also a norepinephrine releasing agent, though with significantly lower potency than for serotonin.
Neuroendocrine effects: Increases prolactin levels, stimulates ACTH release via POMC neurons, and activates oxytocinergic and vasopressinergic neurotransmission.
Pharmacokinetics
Fenfluramine is well absorbed orally with a bioavailability of 68-83%, unaffected by food. It distributes extensively into tissues with a large volume of distribution (11.9 L/kg), reflecting significant tissue binding and accumulation. Peak plasma concentrations occur at 3 hours after a single dose and 4-5 hours at steady state.
The elimination half-life is notably long: 13-30 hours for the parent compound (mean approximately 20 hours), with the d-enantiomer clearing faster (~19 hours) than the l-enantiomer (~25 hours). The active metabolite norfenfluramine has an even longer half-life -- d-norfenfluramine ~34 hours, l-norfenfluramine ~50 hours. This means pharmacological activity persists well beyond the perceived peak of subjective effects.
Steady state is achieved within 4-8 days of regular dosing. Protein binding is approximately 40-50%.
CYP2D6 is a critical metabolic bottleneck. Drugs that inhibit CYP2D6 (including fluoxetine, paroxetine, and quinidine) significantly increase fenfluramine plasma concentrations, creating a dangerous pharmacokinetic interaction on top of the pharmacodynamic serotonin syndrome risk.
Fenfluramine can be administered via oral. The route of administration can influence both the onset and intensity of body load.